Pharmacology: Pharmacodynamics

Pharmacology: Pharmacodynamics — Expert Reference

How it begins

Análisis exhaustivo de los mecanismos moleculares de acción farmacológica: dianas terapéuticas, tipos de receptores, señalización intracelular, modelos matemáticos de interacción fármaco-receptor, agonismo, antagonismo, modulación alostérica, relaciones dosis-respuesta y conceptos emergentes de biagonismo, sesgo de señalización y PROTACs.

What it covers

1. Conceptualization of Pharmacodynamics
2. · Ehrlich's Principle: Corpora non agunt nisi fixata
3. Main Pharmacological Targets
4. · Classification of Pharmacological Receptors
5. G Protein Coupled Receptors (GPCRs)
6. · Molecular Structure of GPCRs
7. · Activation Mechanism and G Protein Cycle
8. · Classes of Gα Proteins and their Effectors
9. Ligand Gated Ion Channel Receivers (LGICs)
10. · Cys-Loop Superfamily (Pentameric)
11. · Glutamate Receptors (Ionotropic)
12. Receptors with Intrinsic Enzymatic Activity
13. · Receptors Tyrosine Kinase (RTK)
14. · Serine/Threonine Kinase Receptors — TGF-β/SMAD Pathway
15. Nuclear Receptors (NR Superfamily)
16. · Modular Structure of Nuclear Receivers
17. · Mechanism of Genomic Action — Steroid Receptors
18. · Non-Genomic Action of Nuclear Receptors
19. Cytokine Receptors and JAK-STAT Pathway
20. Types of Agonism
21. · Allosteric Modulators
22. Concentration-Effect Curves and Pharmacodynamic Parameters
23. · Efficacy vs. Power — Critical Distinction
24. Types of Antagonism
25. · Competitive Antagonism — Quantitative Analysis (Schild Equation)
26. Quantal Dose-Response Relationship (Population)
27. · Sources of Variability in the Quantal Response
28. Main Intracellular Signaling Pathways
29. · Via cAMP / PKA / CREB (Gs → AC)
30. · Via IP3/DAG/Ca²⁺/PKC (Gq → PLCβ)
31. · Via RAS-RAF-MEK-ERK (MAPK)
32. · Via PI3K/AKT/mTOR
33. · NO Route / Guanylate Cyclase / cGMP / PKG
34. Receptor Modulation — Tolerance and Sensitization
35. · Desensitization and Down-Regulation
36. · Up-Regulation
37. · Pharmacological Tolerance and Tachyphylaxis
38. Pharmacological Selectivity
39. · On-Target Effects vs. Off-Target
40. · Intentional Polypharmacology
41. Mathematical Models of Drug-Receptor Interaction
42. · Occupation Model (Clark, 1926)
43. · Two-State Receiver Model (of the Castillo-Katz, 1957)
44. · Spare Receiver Model
45. · Tertiary Model — GPCRs and Allosterism
46. Pharmacodynamic Interactions
47. · Quantitative Synergism and Antagonism
48. · Isobolographic and FICI Analysis
49. Emerging and Advanced Concepts in Pharmacodynamics
50. · Signaling Bias (Biased Agonism)
51. · PROTACs — Directed Protein Degradation
52. · Fragment Pharmacology (FBDD)
53. · Targeted Covalent Drugs
54. Integrated Clinical Correlations
55. · Beta-blockers — Complete Pharmacodynamics
56. · Opioids and µ/κ/δ Receptors
57. · COX inhibitors — NSAIDs
58. · Statins — HMG-CoA Reductase Inhibition
59. · Oncological Immunotherapy — PD-1/PD-L1
60. Therapeutic Index and Pharmacological Safety
61. · PK/PD Models — Integration of Pharmacokinetics and Pharmacodynamics
62. Final Conceptual Integration